Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: Week 52 results from SPIRIT-P2

Genovese M.C.Combe B.Kremer J.M.TSEN-FANG TSAIBehrens F.Adams D.H.Lee C.Kerr L.Nash P.2020-10-222020-10-2220181462-0324https://www.scopus.com/inward/record.uri?eid=2-s2.0-85055605135&doi=10.1093%2frheumatology%2fkey182&partnerID=40&md5=94bccadbcd054ba08cb11d47f388abb6https://scholars.lib.ntu.edu.tw/handle/123456789/517567Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: Week 52 results from SPIRIT-P2journal article10.1093/rheumatology/key182300531622-s2.0-85055605135